2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 265-268
Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Biological Processes, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult
PAPER

376 Real-world outcomes after second CD19-directed CAR T cell treatment for relapsed/refractory B cell acute lymphoblastic leukemia

Matthew P Connor, MD, Amy Zhang, MPH2, Mathew G. Angelos, MD, PhD3, Rawan Faramand, MD4, Tamer Othman, MD5, Karamjeet Singh Sandhu, MD6, Gregory W Roloff, MD7, Jumana Hoque, MBBS8, Yannis K. Valtis I, MD9, Hrishikesh Srinagesh, MD, MSCR10, Evan C. Chen, MD11, Chenyu Lin, MD12, Bhagirathbhai Dholaria, MD, FACP13, Kaitlyn Cecilia Dykes, MD14, Razan Mohty, MD15, Minoo Battiwalla, MD16, Shahbaz Malik, MD17, Luke Mountjoy, DO18, Aravind Ramakrishnan, MD19, Paul Shaughnessy, MD20, Katherine Sutherland, PA21, Navneet Majhail, MD22, Matthew L. Ulrickson, MD23, Omer Jamy, MD24, Marlise Rachael Luskin, MD, MSCE25, Olalekan Oluwole, MD, MPH26, Jae H Park, MD27, Partow Kebriaei, MD28, Nitin Jain, MD29, Elias Jabbour, MD30, Ibrahim Aldoss, MD31, Bijal Shah, MD, MS32, Lori Muffly, MD33, Noelle Frey, MD, MSCE34
1 University of Pennsylvania, Philadephia, Pennsylvania, United States
2 Stanford University School of Medicine, Palo Alto, California, United States
3 University of Colorado, Denver, Colorado, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 University of Chicago School of Medicine, Chicago, Illinois, United States
8 Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Stanford University School of Medicine, Palo Alto, California, United States
11 Dana Farber Cancer Institute, Boston, Massachusetts, United States
12 Duke University School of Medicine, Durham, North Carolina, United States
13 Vanderbilt University School of Medicine, Nashville, Tennessee, United States
14 University of California San Diego School of Medicine, La Jolla, California, United States
15 University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
16 Sarah Cannon Cancer Institute at TriStar Centennial, Nashville, Tennessee, United States
17 Sarah Cannon Transplant & Cellular Therapy Program at Texas Transplant Institute, Austin, Texas, United States
18 Sarah Cannon Transplant & Cellular Therapy Program at Colorado Blood Cancer Institute, Denver, Colorado, United States
19 Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center, Austin, Texas, United States
20 Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, San Antonio, Texas, United States
21 Stanford University School of Medicine, Palo Alto, California, United States
22 Sarah Cannon Cancer Network, Nashville, Tennessee, United States
23 Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
24 University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
25 Dana Farber Cancer Institute, Boston, Massachusetts, United States
26 Vanderbilt University School of Medicine, Nashville, Tennessee, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
31 City of Hope, Duarte, California, United States
32 Moffitt Cancer Center, Tampa, Florida, United States
33 Stanford University School of Medicine, Palo Alto, California, United States
34 University of Pennsylvania, Philadephia, Pennsylvania, United States

Background: CD19-directed chimeric antigen receptor T cells (CART19) are highly effective in relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL), however, 40-50% of patients will experience relapse, often maintaining CD19 expression. Second CART19 treatment has been previously reported in patients who relapsed or lost B cell aplasia after initial CAR T cell therapy. However, data are limited mostly to children, investigational products, and single center experiences. Here we report real-world, multi-center outcomes with brexucabtagene autoleucel (brexu-cel) and obecabtagene autoleucel (obe-cel) administered as a second CART19 therapy.

Methods: Using data compiled by the Real World Outcomes Collaborative for CAR T in ALL (ROCCA) consortium, we identified patients (pts) age ≥18 and treated between 2021-2026 who received at least 2 CART19 therapies for relapsed B-ALL. CART1 included prior investigational CD19-targeting CAR T cells, brexu-cel, obe-cel, or tisagenlecleucel (tisa-cel). CART2 was limited to brexu-cel or obe-cel. The primary endpoint was rate of complete remission with or without count recovery (CR/CRi); key secondary endpoints included rate of measurable residual disease (MRD) negativity, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), event-free survival (EFS), and overall survival (OS). Time-to-event endpoints were estimated using the Kaplan-Meier method with intergroup comparisons made using log-rank tests.

Results: Thirty-four pts received CART2 for R/R B-ALL – 20 brexu-cel and 14 obe-cel. Eight patients (24%) had Philadelphia chromosome(+). Median time between CART1 and CART2 was 16.1 months (range 10.7-23.4). Of those receiving brexu-cel as CART2 (n=20), CART1 included brexu-cel (n=7, 35%), tisa-cel (n=1, 5%), or investigational CART19 (n=12, 60%). Of those receiving obe-cel as CART2 (n=14), CART1 included brexu-cel (n=12, 86%) or investigational CART19 (n=2, 14%). Fourteen patients (41%) had undergone consolidative allogeneic transplant (HCT) between CART1 and CART2.

Median age at CART2 was 35 (25-55). Prior to apheresis for CART2, 10 pts (29%) had >5% marrow blasts, 14 (41%) had MRD+ disease only, and 9 (26%) were MRD-. Sixteen pts (47%) experienced CRS following CART2, all grade 1-2, including 9 (45%) after brexu-cel and 7 (50%) after obe-cel. Nine pts (27%) developed ICANS including 8 (40%) after brexu-cel and 1 (7%) obe-cel. Four patients (12%) had grade 3-4 ICANS, all following brexu-cel. Thirty-one pts (91%) had response assessment after CART2, 2 patients died prior to assessment, 1 lacked response data at time of data cutoff and was excluded from the primary endpoint analysis. Both early deaths (D+14 and D+19) were from infectious complications after obe-cel. Rate of CR/CRi was 82% (brexu-cel: 80%; obe-cel: 85%); 24 pts (73%) achieved MRD- CR. At a median follow-up of 10.8 months (brexu-cel: 16.8; obe-cel: 5.4), median EFS was 5.8 months (brexu-cel: 5.8; obe-cel: 5.6). Median OS was 17.9 months (brexu-cel: 17.9; obe-cel: NR) with a 6-month OS of 84% (95% CI 66-93). Pts with >5% blasts prior to CART2 apheresis (n=10) had a CR/CRi rate of 70% with 50% achieving MRD-. Those in remission prior to CART2 apheresis (n=22) had a CR/CRi rate of 86%, including 82% MRD-. The 6-month cumulative incidence of relapse was 42% (95% CI 22-60). In pts who underwent HCT between CART1 and CART2, median EFS after CART2 was 5.8 months v. 4.2 months in pts who did not receive intervening HCT (p=0.18), while median OS was NR v. 15.7 months (p=0.09). Three patients (9%) underwent HCT following CART2 – 2 as consolidation and 1 after subsequent relapse.

Conclusions: This is the largest multicenter report of adult patients receiving brexu-cel or obe-cel as a second CART19 infusion for recurrent relapse after prior CART19 treatment. In this high risk, heavily pre-treated patient population we found that CART2 was feasible and safe with high rates of MRD- CR. Longer term follow-up is needed to determine the durability of remissions and to better inform the role and timing of consolidative and/or maintenance strategies. Administration of brexu-cel or obe-cel as CART2 can be considered effective therapy in patients who relapse following prior CART19 therapy.

Matthew P Connor, MD: No relevant conflicts of interest to declare.